3D Models of the NCI60 Cell Lines for Screening Oncology Compounds

SLAS Discovery

Volumn 22, Issue 5, 2017, Pages 473-483

  Selby, Mike ^a   Delosh, Rene ^a   Laudeman, Julie ^a   Ogle, Chad ^a   Reinhart, Russell ^a   Silvers, Thomas ^a   Lawrence, Scott ^a   Kinders, Robert ^a   Parchment, Ralph ^a   Teicher, Beverly A ^b   Evans, David M ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

3D; cell culture; NCI60 cells; spheroids; ULA plates

Indexed keywords

CARBOPLATIN; DOXORUBICIN; HISTONE H2AX; SULFORHODAMINE B; TOPOTECAN; ANTINEOPLASTIC AGENT;

ARTICLE; CELL ADHESION; CELL CULTURE TECHNIQUE; CELL VIABILITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESPONSE; DRUG SCREENING; FLUORESCENCE IMAGING; GROWTH RATE; HUMAN; HUMAN CELL; IMAGING SYSTEM; MULTICELLULAR SPHEROID; SPHEROID CELL; THREE DIMENSIONAL CELL CULTURE; TUMOR MICROENVIRONMENT; TUMOR SEEDING; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; SPHEROIDS, CELLULAR;

EID: 85019758241     PISSN: 24725552     EISSN: 24725560     Source Type: Journal    
DOI: 10.1177/2472555217697434     Document Type: Article

References (30)

1. National Cancer Institute. Cell Lines in the In Vitro Screen. https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
2. Shoemaker R. H., Monks A., Alley M. C.. Development of Human Tumor Cell Line Panels for Use in Disease-Oriented Drug Screening. Prog. Clin. Biol. Res. 1988, 276, 265–286.
3. Shoemaker R. H., The NCI60 Human Tumour Cell Line Anticancer Drug Screen. Nat. Rev. Cancer 2006, 6, 813–823.
4. Sausville E. A., Holbeck S. L., Transcription Profiling of Gene Expression in Drug Discovery and Development: The NCI Experience. Eur. J. Cancer 2004, 40, 2544–2549.
5. Hollingshead M. G., Stockwin L. H., Alcoser S. Y.. Gene Expression Profiling of 49 Human Tumor Xenografts from In Vitro Culture through Multiple In Vivo Passages—Strategies for Data Mining in Support of Therapeutic Studies. BMC Genomics 2014, 15, 393–408.
6. Shankavaram U. T., Reinhold W. C., Nishizuka S.. Transcript and Protein Expression Profiles of the NCI-60 Cancer Cell Panel: An Integromic Microarray Study. Mol. Cancer Ther. 2007, 6, 820–832.
7. Kohn K. W., Zeeberg B. R., Reinhold W. C.. Gene Expression Profiles of the NCI-60 Human Tumor Cell Lines Define Molecular Interaction Networks Governing Cell Migration Processes. PLoS ONE 2012, 7, e35716.
8. Weng C-W., Lee S-C., Lee Y-L.. Analysis of the NCI-60 Dataset for Cancer-Related MicroRNA and mRNA Using Expression Profiles. Comp. Biol. Chem. 2013, 44, 15–21.
9. Ehrich M., Turner J., Gibbs P.. Cytosine Methylation Profiling of Cancer Cell Lines. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 4844–4849.
10. Gholami A. M., Hahne H., Wu Z.. Global Proteome Analysis of the NCI-60 Cell Line Panel. Cell Rep. 2013, 4, 609–620.
11. Shankavaram U. T., Varma S., Kane D.. CellMiner: A Relational Database and Query Tool for the NCI-60 Cancer Cell Lines. BMC Genomics 2009, 10, 277–286.
12. Paull K. D., Shoemaker R. H., Hodes L.. Display and Analysis of Patterns of Differential Activity of Drugs against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm. J. Natl. Cancer Inst. 1989, 81, 1088–1092.
13. Holbeck S. L., Collins J. M., Doroshow J. H., Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines. Mol. Cancer Ther. 2010, 9, 1451–1460.
14. Holbeck S. L., Update on NCI In Vitro Drug Screen Utilities. Eur. J. Cancer 2004, 40, 785–793.
15. Johnson J. I., Decker S., Zaharevitz D.. Relationships between Drug Activity in NCI Preclinical In Vitro and In Vivo Models and Early Clinical Trials. Br. J. Cancer 2001, 84, 1424–1431.
16. Hirschhaeuser F., Menne H., Dittfield C.. Multicellular Tumor Spheroids: An Underestimated Tool Is Catching Up Again. J. Biotechnol. 2010, 148, 3–15.
17. Friedrich J., Seidel C., Ebner R.. Spheroid-Based Drug Screen: Considerations and Practical Approach. Nat. Protoc. 2009, 4, 309–324.
18. Rimann M., Graf-Hausner U., Synthetic 3D Multi-Cellular Systems for Drug Development. Curr. Opin. Biotechnol. 2012, 23, 803–809.
19. Fukuda J., Khademhosseini A., Yeo Y.. Micromolding of Photocrosslinkable Chitosan Hydrogel for Spheroid Microarray and Co-cultures. Biomaterials 2006, 27, 5259–5267.
20. Hsiao A. Y., Tung Y-C., Qu X.. 384 Hanging Drop Arrays Give Excellent Z-Factors and Allow Versatile Formation of Co-Culture Spheroids. Biotechnol. Bioeng. 2011, 109, 1293–1304.
21. Imamura Y., Mukohara T., Shimono Y.. Comparison of 2D- and 3D-Culture Models as Drug-Testing Platforms in Breast Cancer. Oncol. Rep. 2015, 33, 1837–1843.
22. Karlsson H., Fryknäs M., Larsson R.. Loss of Cancer Drug Activity in Colon Cancer HCT-116 Cells during Spheroid Formation in a New 3-D Spheroid Cell Culture System. Exp. Cell Res. 2012, 318, 1577–1585.
23. Francia G., Man S., Teicher B.. Gene Expression Analysis of Tumor Spheroids Reveals a Role for Suppressed DNA Mismatch Repair in Multi-Cellular Resistance to Alkylating Agents. Mol. Cell Biol. 2004, 24, 6837–6849.
24. Erlanson M., Daniel-Szolgay E., Carlsson J., Relations between the Penetration, Binding and Average Concentration of Cytostatic Drugs in Human Tumour Spheroids. Cancer Chemother. Pharmacol. 1992, 29, 343–353.
25. Sutherland R. M., Eddy H. A., Bareham B.. Resistance to Adriamycin in Multi-Cellular Spheroids. Int. J. Radiat. Oncol. Biol. Phys. 1979, 5, 1225–1230.
26. McCabe M. T., Ott H. M., Ganji G.. EZH2 Inhibition as a Therapeutic Strategy for Lymphoma with EZH2-Activating Mutations. Nature 2012, 492, 108–112.
27. Dickey J. S., Redon C. E., Nakamura A. J.. H2AX: Functional Roles and Potential Applications. Chromosoma 2009, 118, 683–692.
28. Kinders R. J., Hollingshead M., Lawrence S.. Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity. Clin. Cancer Res. 2010, 16, 5447–5457.
29. Wang L. H., Pfister T. D., Parchment R. E.. Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells. Clin. Cancer Res. 2010, 16, 1073–1085.
30. Bonner W. M., Redon C. E., Dickey J. S.. GammaH2AX and Cancer. Nat. Rev. Cancer 2008, 8, 957–967.